Effects of Montelukast during acute wheezing attack in hospi
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
In chronic asthma treatment, leukotriene receptor antagonists have been recommended. A Study was conducted to investigate the safety and effectiveness of oral montelukast in addition to standard treatment in hospitalized children aged between 6 and 72 months with acute recurrent wheezing attacks.

This randomized, double-blind, placebo-controlled, parallel-group clinical trial involved 100 patients aged 6 to 72 months who had wheezing attacks with clinical asthma scores and were hospitalized.

All the patients were given 0.15mg/kg (maximum 5mg) nebulized salbutamol (8L/min and with 100% O2) with 4h of intervals, 1mg/kg prednisolone (maximum 5 days), nebulized ipratropium bromide (total eight doses) with 6h of intervals. In addition to this treatment, one group received 4mg montelukast, and the other group received a placebo. The CAS of the patients were evaluated with 4h intervals.

Results:
--Total hospital length of stay (LOS) was not different between the montelukast and placebo groups.

--There was no statistically significant difference between the two treatment groups in terms of discharge time, CAS, and oxygen saturation.

Finally, adding montelukast to routine care of patients treated with moderate-to-severe wheezing attacks had no impact on LOS or CAS in the hospital.

Source: https://onlinelibrary.wiley.com/doi/10.1002/ppul.25394?af=R
Like
Comment
Share